Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03990389 · ClinicalTrials.gov registry record · NA

Tracking Depression Symptoms With a Health Chatbot

A NA study of Depression, Postpartum and Depression, Unipolar, sponsored by University of Chicago.

Completed
Registry status
NA
Development phase
31
Enrollment target
2
Study locations

NCT03990389 is a NA study of Depression, Postpartum and Depression, Unipolar that has completed, run by University of Chicago. The registered enrollment target is 31 participants, below the 162-participant average among 15 other Depression, Postpartum trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03990389, a NA study of Depression, Postpartum and Depression, Unipolar, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
2
Study locations

Study Summary

The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators have developed a chatbot which will assist in performing measurement-based care (MBC) via Facebook Messenger. Participants will be randomized to either Usual Care or Usual Care with additional Chatbot Care.

Interventions

  • DEVICE Chatbot Intervention

Study Locations (2)

Illinois

  • University of Chicago - Chicago
  • NorthShore University HealthSystem - Skokie

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2019-02-20
Est. Completion 2020-02-29
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT03990389

The ClinicalTrials.gov registry entry for NCT03990389 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 15 other Depression, Postpartum trials with a reported enrollment target (81% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression, Postpartum appearing as the primary indexed condition, and to 1 intervention - of which Chatbot Intervention is the first listed.

NCT03990389 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03990389 about?

NCT03990389 is a clinical study titled "Tracking Depression Symptoms With a Health Chatbot". The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators have developed a chatbot which will assist in performing measurement-based care (MBC) via Facebook Messenger. Participants will be randomized to either Usual Care or Usual Care ...

What is the current status of trial NCT03990389?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2019-02-20. Estimated completion is 2020-02-29.

What conditions does trial NCT03990389 study?

This clinical trial studies the following conditions: Depression, Postpartum, Depression, Unipolar.

What interventions are being tested in trial NCT03990389?

The interventions under investigation include: Chatbot Intervention (DEVICE).

Who is sponsoring clinical trial NCT03990389?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03990389 being conducted?

This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression, Postpartum

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.